Scarica l'app Stockscreener
6.25
1.26%
-0.08
Precedente Chiudi:
$6.33
Aprire:
$6.41
Volume 24 ore:
15,855
Relative Volume:
0.06
Capitalizzazione di mercato:
$6.78M
Reddito:
$72,100
Utile/perdita netta:
$-4.84M
Rapporto P/E:
-0.8382
EPS:
-7.4566
Flusso di cassa netto:
$-3.84M
1 W Prestazione:
-3.25%
1M Prestazione:
+4.09%
6M Prestazione:
+4.17%
1 anno Prestazione:
-28.20%
Intervallo 1D:
$6.1801
$6.52
Intervallo di 1 settimana:
$6.1801
$6.779
Portata 52W:
$3.315
$15.15
Silo Pharma Inc Stock (SILO) Company Profile
Nome
Silo Pharma Inc
Settore
Industria
Telefono
(718) 400-9031
Indirizzo
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Borsa (SILO) Ultime notizie
SILO PHARMA INC (SILO) Stock Chart - ChartMill
SILO Q4 2023 Earnings: EPS Misses Estimates; Pre-Revenue Biotech Faces Cash Burn ConcernsEarnings Outlook Update - newsline.com
SILO Q4 2023 Earnings: EPS Misses Estimates as Company Advances PipelineDividend Cut Risk - newsline.com
Why Did SILO Stock Soar 85% Today? - Stocktwits
Silo Pharma Implements Reverse Stock Split and Restructures Capital - The Globe and Mail
Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split - Moomoo
Silo Pharma (SILO) completes 1-for-15 reverse stock split and cuts authorized shares - Stock Titan
Silo Pharma Announces 1-for-15 Reverse Stock Split - The Globe and Mail
Silo Pharma announces 1-for-15 reverse stock split effective June 2 - Investing.com UK
Silo Pharma announces 1-for-15 reverse stock split effective June 2 By Investing.com - Investing.com South Africa
Silo Pharma to implement 1-for-15 reverse stock split, issued shares fall to ~1.084M - TradingView
Reverse split shrinks Silo Pharma (NASDAQ: SILO) share count and authorization - Stock Titan
SILO Q4 2023 Earnings: EPS Misses Estimates as Development-Stage Biotech Maintains FocusWeak Earnings Momentum - The Legal Advocate
Silo Pharma Inc. (SILO) Holds Above $0.40 Support After Modest GainsShort Setup Alerts - newsline.com
Silo Pharma (SILO) Surges 5% as Small-Cap Biotech Recovers From Recent LowsSupply Zone - newsline.com
Silo Pharma Inc. (SILO) Rallies 3.99% as Biotech Sentiment Improves — Key Levels in FocusDebt Free Companies - The Legal Advocate
Silo Pharma Inc. (SILO) Q4 2023 Earnings: Widening Losses as Pre-Revenue Biotech Focuses on Pipeline ProgressProfit Margin Analysis - Newser
SILO Q4 2023 Earnings: Biotech Misses EPS Estimates as Pre‑Revenue Phase ContinuesCrowd Stock Picks - Newser
Silo Pharma Inc. (SILO) Edges Higher as Shares Test Key ResistanceAggressive Growth Picks - Newser
Silo Pharma (SILO) Q4 2023 Results Disappoint: What Investors Should KnowRevenue Miss Report - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Earnings: Miss Sparks ConcernTrending Entry Points - Newser
Silo Pharma (SILO) Stock Analysis: Falls -3.79%, Watching $0.35 2026-05-19NHNL Ratio - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Results Miss Estimates — EPS $-0.36 vs $-0.20Special Dividend Alert - newsline.com
Silo Pharma, Inc. (SILO) Q1 2026 10-Q: Financials, Crypto Asset Holdings, and Business Developments - Minichart
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Silo Pharma (NASDAQ: SILO) Q1 loss widens as R&D and crypto costs rise - Stock Titan
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative - citybuzz -
Silo Pharma files patent for ibogaine-based TBI treatment By Investing.com - Investing.com Australia
Silo Pharma files patent for ibogaine-based TBI treatment - Investing.com
With no FDA-approved TBI drugs, Silo pursues ibogaine therapy - Stock Titan
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury - ChartMill
Silo Pharma rallies after securing key patent allowance - MSN
SILO Stock Price, Quote & Chart | SILO PHARMA INC (NASDAQ:SILO) - ChartMill
SILO Silo Pharma reports wider-than-expected Q4 2023 loss, shares dip 1.62% amid weak investor sentiment.High Attention Stocks - Newser
Silo Pharma’S Ptsd Program Advances As FDA Fast-Tracks Psychedelic Therapies For Ptsd - TradingView
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD - GlobeNewswire
Washington speeds psychedelic PTSD work as Silo spotlights program - Stock Titan
Why did SILO stock soar 85% today? - MSN
Levi Strauss, Greenbrier and 3 stocks to watch heading into Tuesday - MSN
SILO Silo Pharma rises 5.57 percent despite reporting a wider than expected Q4 2023 per share loss.Gross Margin - Newser
CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN
SILO Price Today: Silo Pharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
12 Health Care Stocks Moving In Thursday's Pre-Market SessionAxe Compute (NASDAQ:AGPU), Akanda (NASDAQ - Benzinga
Silo Pharma Inc Azioni (SILO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Silo Pharma Inc Azioni (SILO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):